Intracranial and Systemic Response to Alectinib in a Patient with RET-KIF5B Oncogenic Fusion

TY - JOUR

T1 - Intracranial and Systemic Response to Alectinib in a Patient with RET-KIF5B Oncogenic Fusion

AU - Velcheti, Vamsidhar

AU - Ahluwalia, Manmeet

N1 - Oncogenic fusions of rearranged during transfection gene (RET) occur in about 1% to 2% of all NSCLC.1 RET oncogenic fusion partner genes include kinesin family member 5B gene (KIF5B), coiled-coil domain containing 6 gene (CCDC6), nuclear receptor coactivator 4 gene (NCOA4), and FERM-domain containing 4A gene (FMRD4A).2 RET activation in these patients results from the coiled-coil domain from the fusion partners serving as a dimerization unit.

PY - 2017/7/1

Y1 - 2017/7/1

UR - https://www.jto.org/article/S1556-0864(17)30191-0/fulltext

U2 - 10.1016/J.JTHO.2017.03.007

DO - 10.1016/J.JTHO.2017.03.007

M3 - Article

VL - 12

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

ER -